Despite recent earnings growth, the company's P/E ratio is lower than the market, indicating shareholders may think the company has peaked. The company's three-year earnings trends aren't impacting its P/E as anticipated, hinting at potential unseen earnings threats.
Despite Baotou Dongbao Bio-Tech's slightly low ROE, the company's net income growth and inferred efficient management stand out. Although the ROE is lower, significant future earnings growth is anticipated given the high reinvestment rate.
Baotou Dongbao Bio-techに関するコメント
まだコメントはありません